Tealwood Asset Management Inc. Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Tealwood Asset Management Inc. bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,768 shares of the medical equipment provider's stock, valued at approximately $1,182,000.

A number of other institutional investors have also added to or reduced their stakes in LNTH. Vanguard Group Inc. lifted its stake in Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock worth $458,271,000 after purchasing an additional 389,828 shares during the period. Farallon Capital Management LLC lifted its stake in Lantheus by 53.7% during the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock worth $182,999,000 after purchasing an additional 796,000 shares during the period. Westfield Capital Management Co. LP lifted its stake in Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock worth $121,867,000 after purchasing an additional 394,837 shares during the period. Reinhart Partners LLC. lifted its stake in Lantheus by 8.4% during the first quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider's stock worth $91,517,000 after purchasing an additional 114,110 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Lantheus by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock worth $99,525,000 after purchasing an additional 19,071 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on LNTH shares. B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price for the company. JMP Securities cut their target price on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Leerink Partners lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Finally, Truist Financial cut their target price on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average price target of $126.00.

Lantheus Trading Up 1.4 %

LNTH stock traded up $1.50 during trading on Tuesday, hitting $108.10. The company had a trading volume of 486,198 shares, compared to its average volume of 991,907. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $103.67 and a 200-day moving average price of $88.09. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The stock has a market cap of $7.49 billion, a price-to-earnings ratio of 16.51 and a beta of 0.50.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same quarter last year, the firm earned $1.40 EPS. The business's revenue for the quarter was up 22.5% on a year-over-year basis. As a group, analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In related news, Director Gary J. Pruden sold 12,530 shares of Lantheus stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares of the company's stock, valued at $1,138,389.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the sale, the chief accounting officer now owns 62,216 shares in the company, valued at approximately $7,661,900.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Gary J. Pruden sold 12,530 shares of the company's stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the sale, the director now owns 11,978 shares of the company's stock, valued at $1,138,389.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,852 shares of company stock worth $3,922,001. Insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.